In Non-Hodgkin-Lymphoma (NHL) the PI3K subtype specific inhibitor CAL-101 has achieved remarkable therapeutic efficacy [93,94,96] and mechanistic explanation for its anti-tumor activity are promising. Here, PIK3CA is linked to non-Hodgkin lymphoma.